Motley Fool -This is important news since front-end sales typically have higher margins than pharmaceuticals. Basically, front-end sales are everything but prescriptions ...<br><img src="/images/chart_7777cc3.gif" class="ticker-icon" width="14" height="12"><a href="http://finance.google.com/finance?q=WAG&client=news" class="rich">WAG</a><a href="http://www.fool.com/investing/high-growth/2007/07/06/breaking-up-is-easy-to-do.aspx" id=r-6_0>Breaking Up Is Easy to Do</a><br>Motley Fool - 1 hour ago<br>As a separate company, APP can use the cash it generates to invest in new generics, or even buy the rights to branded pharmaceuticals. ...<br><img src="/images/chart_7777cc3.gif" class="ticker-icon" width="14" height="12"><a href="http://finance.google.com/finance?q=ABBI&client=news" class="rich">ABBI</a><a href="http://kansascity.bizjournals.com/kansascity/stories/2007/07/09/story8.html" id=r-7_1117824964>Polsinelli hires a competitor to lead life sciences practice</a><br>Kansas City Business Journal, United States - 1 hour ago<br>Sweeney, a partner with Sonnenschein Nath & Rosenthal LLP until June 29, said his group will focus on clients ranging from human health and pharmaceuticals ...

::Read the Full Article